Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.

doi:10.1158/1078-0432.CCR-14-1756

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Feb 2015

Kim Han Sang, Kwon Hyeong Ju, Jung Inkyung, Yun Mi Ran, Ahn Myung-Ju, Kang Byung Woog, Sun Jong-Mu, Kim Sung Bae, Yoon Dok-Hyun, Park Keon Uk, Lee Se-Hoon, Koh Yoon Woo, Kim Se Hun, Choi Eun Chang, Koo Dong Hoe, Sohn Jin Hee, Kim Bomi, Kwon Nak-Jung, Yun Hwan Jung, Lee Min Goo, Lee Ji Hyun, Kim Tae-Min, Kim Hye Ryun, Kim Joo Hang, Paik Soonmyung, Cho Byoung Chul

Abstract excerpt

PURPOSE: The goals of this study were to investigate the clinical activity, safety, and biomarkers of dacomitinib, an irreversible tyrosine kinase inhibitor of EGFR, HER2, and HER4, in recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M-SCCHN). EXPERIMENTAL DESIGN: Patients were eligible if the diseases were not amenable to curative treatment and had progressed on platinum-based...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Squamous Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Dosage

Share to Head and Neck Neoplasms

Share to Neoplasm Metastasis

Share to Neoplasm Recurrence, Local

Share to Quinazolinones

Share to Retreatment

Share to Squamous Cell Carcinoma of Head and Neck

Source

Open in PubMed

Identifiers

PMID: 25424851
DOI: 10.1158/1078-0432.CCR-14-1756

Genes

EGFR
PTEN
TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.PMID 25424851Read ↗

Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma.Semantic proximity Read ↗

Predictive and prognostic factors for immunotherapy response in head and neck squamous cell carcinoma: a narrative review.Semantic proximity Read ↗

Immunotherapy with PD-1 Inhibitor Nivolumab in Recurrent/Metastatic Platinum Refractory Head and Neck Cancers: The Early Experience of Two Academic CenterSemantic proximity Read ↗

Exploratory Biomarker Analysis of Abemaciclib in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma With Dysregulated CDK4/6 Pathway.Semantic proximity Read ↗

Expression of PD-L1, PD-L2, and inflammatory gene expression profile in locally advanced head and neck squamous cell carcinomaSemantic proximity Read ↗

Personalized circulating tumor DNA dynamics predict survival and response to immune checkpoint blockade in recurrent/metastatic head and neck cancerSemantic proximity Read ↗

High-Sensitivity PD-L1 Staining Using Clone 73-10 Antibody and Spatial Transcriptomics for Precise Expression Analysis in Non-Tumorous, Intraepithelial neoplasia, and Squamous Cell Carcinoma of Head and NeckSemantic proximity Read ↗

Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma (Review)Semantic proximity Read ↗

PD-L1 expression combined with immune phenotype is a potential predictor of outcome with PD-1 inhibitor monotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma.Semantic proximity Read ↗

Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.Semantic proximity Read ↗

Circulating tumour DNA kinetics in recurrent/metastatic head and neck squamous cell cancer patientsSemantic proximity Read ↗

Multicenter validation of an assay to predict anti-PD-1 disease control in patients with recurrent or metastatic Head and Neck Squamous Cell Carcinoma: The PREDAPT StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.